NRX Pharmaceuticals: Promising Growth Potential with HOPE Clinics and KETAFREE Innovations
I'm PortAI, I can summarize articles.
Thomas Shrader from BTIG maintained a Buy rating on NRX Pharmaceuticals with a $25.00 price target, citing the growth potential of HOPE clinics and KETAFREE innovations. HOPE clinics aim to provide effective treatments for high-risk groups, while KETAFREE targets the ketamine market. The company's stock has dropped 35.97% in the past six months, from $3.670 to $2.350.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments